Zealand Pharma — November 2022
-
Upcoming events
• Initiate Phase 1b MAD trial of ZP8396, a long-acting amylin analogue in development for obesity by the end of the fourth quarter 2022.
• Interim Phase 3 data from EASE-SBS 2 and 3 long term extension trials of glepaglutide expected by the end of the fourth quarter 2022, and first quarter of 2023, respectively. -
ser i noget "breaking"?
-
ZEAL - Financial Results for the First Nine Months 2022 https://www.proinvestor.com/boards/107722
-
tak
-
Non event.
-
Zealand Pharma hosted a conference call on November 10 at 4pm CET (10am ET) to present third quarter results for 2022.
-
Jeg er klar
-
Der var ikke mange spørgsmål "fra salen" men det kan skyldes at operator havde problmer med forbindelsen.
-
Ingen overraskelser i det C
onference call -
tak
-
Det var en fin lille gennemgang af situationen. Finacial targets bliver fastholdt og ingen overraskelser. Jeg troet at BI var lidt længere fremme end det som blev fremlagt. Men det er min fejl at jeg ikke havde styr på dette.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind